Sara Hurvitz, MDDirector, Breast Cancer Clinical Research Program
Part 2/2 on a discussion of Managing Breast Cancer. Part 1 was presented on Wednesday, October 13.
*Identify patients with breast cancer who may benefit from treatment with phosphoinositide 3-kinase (PI3K) inhibitors.
*Apply key clinical trial data surrounding the novel and emerging PI3K inhibitors for the development of a treatment plan for patients with breast cancer.
*Monitor for AEs resulting from PI3K inhibitors and implement mitigation strategies.
Breast cancer in its advanced stages is incurable, and treatment is largely palliative in nature. However, it is nonetheless effective as it may reduce tumor burden, alleviate symptoms, and prolong progression. The emergence of PI3K inhibitors into the therapeutic landscape has expanded treatment options for patients with breast cancers, yet many clinicians are unfamiliar with how to best incorporate these agents into treatment plans for their patients with breast cancer. This case-based module provides clinicians with high-level instruction that will better enable them to use PI3K inhibitors in their clinical practice to optimize outcomes for eligible patients with breast cancer. A leading oncology expert will use a real-world clinical scenario to hone in on how to best identify patients who would benefit from PI3K inhibitor therapy, apply pivotal trial data to clinical decision-making and manage AEs associated with these agents.
This event is sponsored by Clinical Care Solutions and is not sponsored by industry.